查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2017223

鬱血性心臟衰竭治療設備市場：按設備類型、治療方法、最終用戶和分銷管道分類－2026-2032年全球市場預測

Congestive Heart Failure Treatment Device Market by Device Type, Therapeutic Modality, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，鬱血性心臟衰竭設備市場價值將達到 145.6 億美元，到 2026 年將成長至 156.4 億美元，到 2032 年將達到 267.6 億美元，複合年成長率為 9.07%。

主要市場統計數據
基準年 2025 145.6億美元
預計年份：2026年 156.4億美元
預測年份 2032 267.6億美元
複合年成長率 (%) 9.07%

本文簡要概述了臨床、技術和商業性促進因素如何匯聚，從而重塑鬱血性心臟衰竭器械治療的選擇和治療路徑。

鬱血性心臟衰竭仍然是最嚴重的慢性心血管疾病之一，給臨床系統、診療路徑和醫療設備創新者都帶來了巨大壓力。過去十年，治療模式已從症狀管理發展到利用醫療設備進行干預，這些器械旨在調節心臟電生理功能並提供機械循環支援。這些轉變反映了植入技術、手術全期護理和長期監測方面的進步，也對醫療設備的耐用性、患者的生活品質以及後續治療的經濟性提出了新的要求。

技術小型化、數位連接和基於價值的護理模式如何推動設備開發和臨床應用領域的變革。

隨著電刺激、機械循環支援和數位醫療領域的創新融合，新的治療標準不斷湧現，鬱血性心臟衰竭的治療設備格局正在迅速變化。設備小型化、電池技術以及軟體主導的治療調節技術的進步，拓展了植入式心臟整流去顫器（ICD）和心臟再同步治療（CRT）設備的臨床適應症和應用範圍。同時，心室輔助裝置（VAD）也受益於材料的改進、經皮方法的進步以及先進的血流動力學控制演算法，這些技術降低了術前術後風險，並擴大了長期支持的範圍。

美國不斷變化的關稅和貿易政策趨勢對採購、製造在地化和臨床供應連續性的累積定性影響。

美國近期的關稅趨勢正對鬱血性心臟衰竭設備生態系統產生累積影響，波及籌資策略、製造地和商業性利潤率。進口關稅的增加和貿易政策的不確定性促使許多製造商重新評估全球供應鏈，加快供應商多元化，並探索區域性製造地，以降低跨境成本波動帶來的風險。這些調整的驅動力在於對高度敏感的醫療設備組件（例如專用半導體、植入式電池和專有感測器）的需求不斷成長，而這些組件極易受到地緣政治供應限制的影響。

在治療心臟衰竭的過程中，醫療設備類型、治療方法、終端用戶環境和分銷管道如何相互作用，從而影響醫療設備普及和商業策略的促進因素？

細分市場分析揭示了不同醫療設備類型、治療方法、終端用戶和分銷管道的需求促進因素和部署模式各不相同。就醫療設備類型而言，心臟再同步治療裝置和植入式心臟整流去顫器越來越注重演算法同步和心律不整預防。同時，心室輔助裝置需要特殊的介入性手術途徑和長期的門診支援。在心室輔助裝置中，左心室輔助裝置是晚期左心臟衰竭持續支持的重點，而雙心室和右心室輔助裝置在複雜血流動力學病例中仍然至關重要，並且通常需要多學科醫療團隊的協作。

決定美洲、歐洲、中東和非洲以及亞太市場採用模式和戰略重點的區域臨床、監管和商業性趨勢。

區域趨勢持續影響美洲、歐洲、中東和非洲以及全部區域的臨床導入模式、監管路徑和商業策略。在美洲，整合的醫療保健系統和先進的報銷機制往往推動了實證器械療法和打包式醫療模式的快速普及。同時，公共和私人支付方之間的區域差異影響著採購週期和價格談判。在歐洲、中東和非洲，監管協調的努力與不同的報銷環境並存，促使製造商制定區域性的臨床證據策略和選擇性的市場進入順序，以符合各國醫療技術評估的優先事項。

區分市場領導者的策略重點包括創造能夠產生競爭優勢的證據、平台模組化以及以服務為導向的商業模式。

在鬱血性心臟衰竭醫療設備領域，各公司正優先考慮臨床證據的累積、平台模組化以及以服務為導向的商業模式，以在競爭激烈的市場環境中脫穎而出。主要企業正投資於縱向療效研究和註冊登記整合，以證明其產品能夠降低再入院率並改善病患功能狀態。同時，產品藍圖強調互通性、軟體主導的治療最佳化以及能夠延長設備生命週期的升級，從而透過服務合約和遠端監控訂閱創造持續的商機。

為醫療設備製造商和供應商合作夥伴提供實用策略指南，以確保產品滲透率、管理價格波動風險並推動永續的商業性成果。

即使面臨技術和政策方面的挑戰，產業領導企業也應推動一系列合作舉措，以維護臨床信譽、加速產品應用並保障利潤率。首先，他們應優先在不同患者群體和真實臨床環境中收集可靠的臨床證據，以支持醫療保險報銷申請並證明療效的相對優勢。其次，他們應實現零件來源多元化，認證替代供應商，並投資本地製造或組裝能力，以降低關稅和物流風險。第三，他們應設計模組化醫療設備平台和軟體升級路徑，以實現分階段創新、降低產品過時風險，並透過服務交付實現持續收入。

我們的策略建議以透明、穩健的混合方法研究途徑為支撐，該方法結合了相關人員對話、臨床證據檢驗和供應鏈分析。

本分析的調查方法結合了結構化的一手研究（與產業相關人員合作）和全面的二手資料檢驗，確保了分析結果的平衡性和可驗證性。一手研究包括對臨床醫生、採購經理、醫療設備營運經理和監管專家的結構化訪談，從而能夠定性地了解推廣應用障礙、臨床工作流程和醫院決策標準。二手資料包括同行評審的臨床文獻、醫療設備註冊資訊、監管申報文件和已發表的臨床試驗結果，為技術性能和安全性考量提供了實證依據。

結論強調，持續的臨床證據、穩健的營運結構和適應性強的商業模式對於確保長期成功至關重要。

總之，目前鬱血性心臟衰竭治療設備的現狀受到臨床創新、監管審查和不斷演變的商業模式相互作用的影響，這要求企業採取靈活的策略並嚴格執行。電刺激、機械循環支援和數位化監測等方面的技術進步不斷拓展治療選擇，而保險公司和醫療服務提供者則要求獲得可驗證的療效和對整體醫療成本的可預測影響。貿易趨勢和關稅壓力進一步增加了營運的複雜性，迫使製造商重新考慮採購和製造地，以確保供應的連續性和獲利能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：鬱血性心臟衰竭治療器材市場：依器械類型分類

  • 心臟再同步治療裝置
  • 植入式心臟整流去顫器
  • 心室輔助裝置
    • 雙心室輔助裝置
    • 左心室輔助裝置
    • 右心室輔助裝置

第9章 依治療方法鬱血性心臟衰竭設備市場

  • 電刺激
    • 非同步心律調節器
    • 同步心律調節器
  • 機械循環輔助

第10章：鬱血性心臟衰竭治療設備市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第11章：鬱血性心臟衰竭治療器械市場：按分銷管道分類

  • 直銷
  • 銷售代理
  • 線上銷售

第12章鬱血性心臟衰竭設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：鬱血性心臟衰竭治療器材市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：鬱血性心臟衰竭治療器材市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國鬱血性心臟衰竭器械市場

第16章：中國鬱血性心臟衰竭器材市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Abiomed, Inc.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Getinge AB
  • Jarvik Heart Inc.
  • LivaNova PLC
  • Medtronic plc
  • MicroPort Scientific Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • SynCardia Systems LLC
Product Code: MRR-036CEF508588

The Congestive Heart Failure Treatment Device Market was valued at USD 14.56 billion in 2025 and is projected to grow to USD 15.64 billion in 2026, with a CAGR of 9.07%, reaching USD 26.76 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.56 billion
Estimated Year [2026] USD 15.64 billion
Forecast Year [2032] USD 26.76 billion
CAGR (%) 9.07%

Concise framing of how clinical, technological, and commercial drivers converge to reshape congestive heart failure device treatment choices and pathways

Congestive heart failure remains one of the most consequential chronic cardiovascular conditions, exerting pressure on clinical systems, care pathways, and device innovators alike. Over the past decade, treatment paradigms have evolved from symptom management toward device-enabled interventions that target electrical coordination and mechanical circulatory support. These shifts reflect advances in implantable technologies, perioperative care, and longitudinal monitoring, and they have created new expectations around device durability, patient quality of life, and downstream care economics.

As clinical teams increasingly integrate remote monitoring and evidence-based selection criteria, manufacturers and providers must align product design with real-world usability and long-term outcomes. Concurrently, regulatory rigor and payer scrutiny demand robust clinical evidence and demonstrable cost-effectiveness. Therefore, stakeholders must balance clinical innovation with pragmatic considerations such as supply chain resilience, distribution models, and end-user training. This introduction frames the subsequent sections by identifying the interconnected clinical, technological, and commercial drivers that dictate near-term strategic choices for device makers, hospital systems, and specialty clinics.

How technological miniaturization, digital connectivity, and value-based care models are driving transformative shifts across device development and clinical adoption landscapes

The landscape for congestive heart failure devices is changing rapidly as innovations in electrical stimulation, mechanical circulatory support, and digital health converge to enable new standards of care. Advances in device miniaturization, battery technology, and software-driven therapy adjustment have expanded the clinical indications and usability of implantable cardioverter defibrillators and cardiac resynchronization therapy devices. Simultaneously, ventricular assist devices are benefitting from improved materials, percutaneous approaches, and enhanced hemodynamic control algorithms that reduce perioperative risk and broaden candidacy for durable support.

In parallel, health systems are adopting value-based procurement and outcomes-linked contracting, which compels manufacturers to prioritize long-term survivorship data, reduced rehospitalization rates, and integrated service models. Digital connectivity has introduced remote patient monitoring as an integral adjunct to device therapy, enabling timely interventions and lowering the burden on acute care settings. Consequently, market participants are shifting from transactional product sales toward comprehensive service portfolios, bundled care offerings, and collaborative care pathways. These transformative shifts demand that clinical, commercial, and regulatory strategies be tightly aligned to maintain competitiveness and to deliver measurable improvements in patient outcomes.

Cumulative qualitative impacts of evolving United States tariff and trade policy dynamics on sourcing, manufacturing localization, and clinical supply continuity

Recent tariff dynamics in the United States have had a cumulative effect on the congestive heart failure device ecosystem, influencing sourcing strategies, manufacturing footprints, and commercial margins. Increased import duties and trade policy uncertainty have prompted many manufacturers to reassess global supply chains, accelerate supplier diversification, and explore regional manufacturing hubs to reduce exposure to cross-border cost volatility. These adjustments have taken place against a backdrop of increased demand for advanced device components such as specialized semiconductors, implantable-grade batteries, and proprietary sensors, all of which are sensitive to geopolitical supply constraints.

As a result, procurement teams and manufacturers have invested in dual-sourcing, qualified secondary suppliers, and enhanced inventory management to mitigate lead-time risk. Meanwhile, service models that rely on consumable components have been recalibrated to account for higher landed costs and potential delays in component availability. Regulatory filings and quality-management systems have also required updates to reflect new sourcing arrangements and to maintain continuity of clinical trials and post-market surveillance. In aggregate, these cumulative impacts have favored organizations that can rapidly adapt sourcing strategies, maintain transparent supplier relationships, and pass through or absorb cost changes while sustaining clinical support and warranty obligations.

How device type, therapeutic modality, end-user settings, and distribution channels interact to shape adoption drivers and commercial strategies in congestive heart failure treatments

Segmentation insights reveal differentiated demand drivers and adoption patterns across device type, therapeutic modality, end users, and distribution channels. When considering device type, cardiac resynchronization therapy devices and implantable cardioverter defibrillators increasingly center on algorithmic synchronization and arrhythmia prevention, while ventricular assist devices require distinct surgical pathways and long-term outpatient support. Within ventricular assist devices, left ventricular assist devices have become the focal point for durable support in advanced left-sided failure, whereas biventricular assist devices and right ventricular assist devices remain crucial for complex hemodynamic cases, often necessitating multi-disciplinary care teams.

Across therapeutic modality, electrical stimulation pathways leverage asynchronous and synchronous pacemaker approaches to restore coordinated contraction and reduce symptomatic burden, while mechanical circulatory support provides direct hemodynamic restoration for patients with advanced or refractory failure. End users exhibit clear differentiation: hospitals manage the full spectrum of acute implantation and complex perioperative care, ambulatory surgical centers facilitate selected device implantations and follow-up for lower-risk procedures, and specialty clinics deliver device management, optimization, and long-term monitoring that drive adherence and early complication detection. Moreover, distribution channel behavior stratifies commercial engagement and adoption cadence; direct sales enable close collaboration with large hospital systems and integrated service contracts, distributors facilitate reach into regional hospital networks and specialty clinics, and online sales platforms create opportunities for standardized consumables, accessories, and remote service subscriptions. Taken together, these segmentation lenses inform targeted product development, tailored clinical training programs, and adaptive go-to-market models that match clinical complexity with appropriate distribution and service investments.

Regional clinical, regulatory, and commercial dynamics that determine adoption patterns and strategic priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics continue to shape clinical adoption patterns, regulatory pathways, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated health systems and advanced reimbursement structures often favor rapid adoption of evidence-backed device therapies and bundled-care models, while regional differences between public and private payers influence procurement cycles and price negotiations. Moving to Europe, Middle East & Africa, regulatory harmonization efforts coexist with heterogeneous reimbursement environments, prompting manufacturers to deploy region-specific clinical evidence strategies and selective market-entry sequencing to align with national health technology assessment priorities.

In the Asia-Pacific region, the combination of rising prevalence, expanding specialist capacity, and an expanding middle class is accelerating demand; however, manufacturers must tailor device designs and pricing strategies to accommodate varied infrastructure, hospital capabilities, and local regulatory processes. Across all regions, supply chain localization, clinical training partnerships, and investments in remote monitoring infrastructure have emerged as essential components of successful market penetration. By strategically aligning clinical evidence generation, reimbursement modeling, and distribution investments to regional nuances, organizations can maximize adoption while mitigating regulatory and operational risks.

Strategic priorities that distinguish market leaders including evidence generation, platform modularity, and service-oriented commercial models driving competitive advantage

Companies active in congestive heart failure devices are prioritizing clinical evidence generation, platform modularity, and service-oriented commercial models to differentiate in a competitive environment. Leading firms are investing in longitudinal outcome studies and registry integration to demonstrate reductions in rehospitalization and improvements in functional status. Concurrently, product roadmaps emphasize interoperability, software-driven therapy optimization, and upgrades that extend device lifecycles, which enables recurring revenue opportunities through service contracts and remote monitoring subscriptions.

Strategic partnerships with hospitals and specialty clinics are being used to accelerate real-world data collection and to co-develop clinical pathways that ease adoption. In addition, many organizations are pursuing targeted manufacturing investments, including localized production and quality-system enhancements, to reduce exposure to geopolitical risk and tariff fluctuations. Mergers and acquisitions remain an active lever for acquiring niche technologies such as advanced sensors, novel battery chemistry, or AI-enabled diagnostics, while licensing and joint-development agreements allow larger players to expand portfolios without diluting core competencies. Overall, companies that balance disciplined clinical evidence programs with adaptive commercial execution and resilient operational models are best positioned to capture long-term clinical and economic value.

Actionable strategic playbook for device manufacturers and provider partners to secure adoption, manage tariff exposure, and drive durable commercial outcomes

Industry leaders should pursue a set of coordinated actions to preserve clinical credibility, accelerate adoption, and protect margins amidst technological and policy headwinds. First, prioritize generation of robust clinical evidence across diverse patient cohorts and real-world settings to support reimbursement discussions and to demonstrate comparative effectiveness. Second, diversify component sourcing and qualify alternate suppliers while investing in regional manufacturing or assembly capabilities to reduce tariff and logistical exposure. Third, design modular device platforms and software upgrade paths that permit incremental innovation, reduce obsolescence risks, and enable recurring revenue through service offerings.

Additionally, foster deep clinical partnerships with hospitals, specialty clinics, and ambulatory surgical centers to co-create streamlined care pathways and targeted training that reduce implantation complications and optimize follow-up. Integrate remote monitoring and patient-engagement tools to maintain continuity of care and to provide data that supports value-based contracting. Finally, conduct scenario planning for regulatory and tariff shifts, align pricing strategies with payer expectations, and develop clear commercial playbooks for direct sales, distributor partnerships, and digital channels to ensure market coverage and sustainable growth.

Transparent and robust mixed-methods research approach combining stakeholder engagement, clinical evidence review, and supply chain analysis to underpin strategic recommendations

The research methodology underpinning this analysis combined structured primary engagement with industry stakeholders and comprehensive secondary evidence review to ensure balanced, verifiable insights. Primary research included structured interviews with clinicians, procurement leaders, device operations managers, and regulatory experts, enabling qualitative understanding of adoption barriers, clinical workflows, and hospital decision criteria. Secondary inputs comprised peer-reviewed clinical literature, device registries, regulatory filings, and publicly disclosed clinical trial outcomes, which provided empirical context for technology performance and safety considerations.

Analytical rigor was maintained through cross-validation of stakeholder testimony with published evidence and regulatory documentation, and by employing scenario-based sensitivity checks for supply chain and policy variables. Limitations include the inherent lag between ongoing clinical trials and regulatory decisions, and the variability of regional reimbursement frameworks that can affect short-term adoption. To mitigate these constraints, the methodology prioritized triangulation, transparent assumption disclosure, and consultation with clinical and commercial advisory panels to ground recommendations in practical realities.

Concluding synthesis emphasizing the imperative for aligned clinical evidence, resilient operations, and adaptive commercial models to secure long-term success

In conclusion, the congestive heart failure device landscape is defined by converging forces of clinical innovation, regulatory scrutiny, and shifting commercial models that require agile strategy and disciplined execution. Technological advances in electrical stimulation, mechanical circulatory support, and digital monitoring continue to expand therapeutic options, while payers and providers demand demonstrable outcomes and predictable total-cost-of-care impacts. Trade dynamics and tariff pressures have introduced additional operational complexity, compelling manufacturers to rethink sourcing and manufacturing footprints to maintain supply continuity and margin integrity.

Moving forward, successful organizations will integrate rigorous clinical evidence programs with modular product architectures, resilient supply chains, and adaptive go-to-market models that reflect regional nuances. By aligning clinical partnerships, reimbursement engagement, and digital service offerings, stakeholders can accelerate adoption, improve patient outcomes, and build sustainable commercial franchises that withstand policy and market volatility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Congestive Heart Failure Treatment Device Market, by Device Type

  • 8.1. Cardiac Resynchronization Therapy Device
  • 8.2. Implantable Cardioverter Defibrillator
  • 8.3. Ventricular Assist Device
    • 8.3.1. Biventricular Assist Device
    • 8.3.2. Left Ventricular Assist Device
    • 8.3.3. Right Ventricular Assist Device

9. Congestive Heart Failure Treatment Device Market, by Therapeutic Modality

  • 9.1. Electrical Stimulation
    • 9.1.1. Asynchronous Pacemakers
    • 9.1.2. Synchronous Pacemakers
  • 9.2. Mechanical Circulatory Support

10. Congestive Heart Failure Treatment Device Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Congestive Heart Failure Treatment Device Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
  • 11.3. Online Sales

12. Congestive Heart Failure Treatment Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Congestive Heart Failure Treatment Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Congestive Heart Failure Treatment Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Congestive Heart Failure Treatment Device Market

16. China Congestive Heart Failure Treatment Device Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Abiomed, Inc.
  • 17.7. Biotronik SE & Co. KG
  • 17.8. Boston Scientific Corporation
  • 17.9. Getinge AB
  • 17.10. Jarvik Heart Inc.
  • 17.11. LivaNova PLC
  • 17.12. Medtronic plc
  • 17.13. MicroPort Scientific Corporation
  • 17.14. Otsuka Pharmaceutical Co., Ltd.
  • 17.15. SynCardia Systems LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ASYNCHRONOUS PACEMAKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ASYNCHRONOUS PACEMAKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ASYNCHRONOUS PACEMAKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SYNCHRONOUS PACEMAKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SYNCHRONOUS PACEMAKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SYNCHRONOUS PACEMAKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY MECHANICAL CIRCULATORY SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY MECHANICAL CIRCULATORY SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY MECHANICAL CIRCULATORY SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. G7 CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. G7 CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. G7 CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. NATO CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NATO CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY ELECTRICAL STIMULATION, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)